MXPA05013340A - Composiciones y metodos para liberacion mucosal incrementada de la hormona del crecimiento. - Google Patents

Composiciones y metodos para liberacion mucosal incrementada de la hormona del crecimiento.

Info

Publication number
MXPA05013340A
MXPA05013340A MXPA05013340A MXPA05013340A MXPA05013340A MX PA05013340 A MXPA05013340 A MX PA05013340A MX PA05013340 A MXPA05013340 A MX PA05013340A MX PA05013340 A MXPA05013340 A MX PA05013340A MX PA05013340 A MXPA05013340 A MX PA05013340A
Authority
MX
Mexico
Prior art keywords
growth hormone
subject
methods
delivery
blood plasma
Prior art date
Application number
MXPA05013340A
Other languages
English (en)
Inventor
Shyam Vangala
Original Assignee
Nastech Pharm Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nastech Pharm Co filed Critical Nastech Pharm Co
Publication of MXPA05013340A publication Critical patent/MXPA05013340A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH] (Somatotropin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

Se describen formulaciones farmaceuticas que comprenden por lo menos una hormona del crecimiento y uno o mas agentes incrementadores de liberacion intranasales para la liberacion mucosal nasal incrementada de la hormona del crecimiento. En un aspecto, las formulaciones y metodos de liberacion intranasales proporcionan liberacion incrementada de la hormona del crecimiento al plasma sanguineo, por ejemplo, rindiendo una concentracion maxima (Cmax) de la hormona del crecimiento en una vena portal hepatica o un plasma sanguineo del sujeto que es 20% o mas grande comparado con una concentracion maxima de la hormona del crecimiento en la vena portal hepatica o del pasma sanguineo del sujeto despues de la administracion al sujeto de una misma concentracion o dosis de la hormona del crecimiento al sujeto por inyeccion subcutanea. Las formulaciones y los metodos de ejemplo de la invencion utilizan la hormona humana del crecimiento como la hormona.
MXPA05013340A 2003-06-09 2004-06-01 Composiciones y metodos para liberacion mucosal incrementada de la hormona del crecimiento. MXPA05013340A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47740303P 2003-06-09 2003-06-09
PCT/US2004/017632 WO2005004895A2 (en) 2003-06-09 2004-06-01 Compositions and methods for enhanced mucosal delivery of growth hormone

Publications (1)

Publication Number Publication Date
MXPA05013340A true MXPA05013340A (es) 2006-03-09

Family

ID=34061913

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05013340A MXPA05013340A (es) 2003-06-09 2004-06-01 Composiciones y metodos para liberacion mucosal incrementada de la hormona del crecimiento.

Country Status (6)

Country Link
US (1) US20050031549A1 (es)
EP (1) EP1643970A2 (es)
JP (1) JP2007500243A (es)
CA (1) CA2528465A1 (es)
MX (1) MXPA05013340A (es)
WO (1) WO2005004895A2 (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050002867A1 (en) * 1997-10-01 2005-01-06 Novadel Pharma Inc. Buccal, polar and non-polar sprays containing propofol
US20020141970A1 (en) * 2001-03-05 2002-10-03 Pettit Dean K. Stable aqueous solutions of granulocyte macrophage colony-stimulating factor
US7404489B1 (en) 2003-03-04 2008-07-29 Qol Medical, Llc Cyanocobalamin low viscosity aqueous formulations for intranasal delivery
US20050129679A1 (en) * 2003-12-15 2005-06-16 Nastech Pharmaceutical Company Inc. Method for opening tight junctions
US20060182692A1 (en) * 2003-12-16 2006-08-17 Fishburn C S Chemically modified small molecules
EP1888103B1 (en) * 2005-04-11 2012-03-21 Amylin Pharmaceuticals, Inc. Use of glp-1, exendin and agonists thereof to delay or prevent cardiac remodeling
ATE501248T1 (de) * 2005-07-02 2011-03-15 Arecor Ltd Stabile wässrige systeme mit proteinen
CU23317A1 (es) * 2005-07-22 2008-10-22 Ct De Investigacia N Y Desarro Formulaciones nasales de eporh con bajo contenido de ã cido siã lico para el tratamiento de enfermedades del sistema nervioso central
WO2007022345A2 (en) 2005-08-17 2007-02-22 Fleming And Company, Pharmaceuticals Vitamin b12 nasal spray and method of use
GB0604319D0 (en) * 2006-03-03 2006-04-12 Optinose As Nasal delivery
US7425542B2 (en) * 2006-06-23 2008-09-16 Aegis Therapeutics, Inc. Stabilizing alkylglycoside compositions and methods thereof
US8084022B2 (en) * 2006-06-23 2011-12-27 Aegis Therapeutics, Llc Stabilizing alkylglycoside compositions and methods thereof
US7998927B2 (en) * 2006-06-23 2011-08-16 Aegis Therapeutics, Llc Stabilizing alkylglycoside compositions and methods thereof
WO2008006019A2 (en) * 2006-07-06 2008-01-10 Advisys Inc. Growth hormone releasing hormone treatment to decrease cholesterol levels
CA2939778C (en) 2007-01-31 2019-01-29 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
EP2142562B1 (en) 2007-03-28 2013-07-03 President and Fellows of Harvard College Stitched polypeptides
AU2008274938A1 (en) * 2007-07-11 2009-01-15 Aerovance, Inc. Pharmaceutical polypeptide dry powder aerosol formulation and method of preparation
EP2457590B1 (en) * 2008-05-01 2014-12-24 Arecor Limited Protein formulation
EP2341940A1 (en) * 2008-07-16 2011-07-13 Arecor Limited The stabilisation of proteins
EP2328607A1 (en) * 2008-07-16 2011-06-08 Arecor Limited Stable formulation of a therapeutic protein
KR20110056516A (ko) * 2008-09-12 2011-05-30 크리티컬 파머수티컬스 리미티드 점막 또는 피부를 통한 치료제의 흡수 개선
US8592381B2 (en) 2008-12-18 2013-11-26 Rhamnopharma Inc. Method for treating rhinitis and sinusitis by rhamnolipids
WO2010080406A1 (en) * 2008-12-18 2010-07-15 Adrem Biotech, Inc. Method for treating rhinitis and sinusitis by rhamnolipids
KR20120116421A (ko) * 2009-11-25 2012-10-22 주식회사 메디진바이오 성장 호르몬을 포함하는 흡입형 분말 제제의 ｎｍｄａ 수용체 기능저하-관련 질환을 예방 또는 치료하기 위한 용도
EP2356998A1 (en) * 2010-02-17 2011-08-17 Université de Liège A pharmaceutical composition for treatment of thrombosis-related diseases comprising a fragment of prolactin (PRL)-growth hormone (GH) - placental lactogen (PL)-family protein
UA111162C2 (uk) 2010-08-04 2016-04-11 Флекшен Терап'Ютікс, Інк. Ін'єкційна композиція ацетоніду триамцинолону для лікування болю
EP2603600B1 (en) 2010-08-13 2018-11-21 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
AU2012253701A1 (en) * 2011-05-10 2013-11-21 Nestec S.A. Methods and compositions for preserving lean body mass during weight loss
BR112013028723A2 (pt) * 2011-05-10 2016-08-09 Nestec Sa métodos e composições para promover o crescimento da massa corporal magra
ES2642312T3 (es) * 2011-08-04 2017-11-16 Flexion Therapeutics, Inc. Corticosteroides para el tratamiento del dolor de articulaciones
KR20140100937A (ko) 2011-10-18 2014-08-18 에일러론 테라퓨틱스 인코포레이티드 펩티도미메틱 거대고리
WO2013123266A1 (en) 2012-02-15 2013-08-22 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
JP6450192B2 (ja) 2012-02-15 2019-01-09 エイルロン セラピューティクス，インコーポレイテッド トリアゾール架橋した、およびチオエーテル架橋したペプチドミメティック大環状化合物
US9604919B2 (en) 2012-11-01 2017-03-28 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
JP5797227B2 (ja) * 2013-05-21 2015-10-21 パル ファーマシューティカル， インコーポレーテッド 鼻内送達用シアノコバラミン低粘度水性製剤
BR112017005598A2 (pt) 2014-09-24 2017-12-12 Aileron Therapeutics Inc macrociclos peptidomiméticos e usos dos mesmos
EP3294318A4 (en) 2015-03-20 2019-04-03 Aileron Therapeutics, Inc. PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF
JP6097787B2 (ja) * 2015-06-09 2017-03-15 パル ファーマシューティカル， インコーポレーテッド 鼻内送達用シアノコバラミン低粘度水性製剤
WO2018020386A1 (en) * 2016-07-27 2018-02-01 Sun Pharmaceutical Industries Limited Topical spray system of halobetasol
CN116617384A (zh) * 2017-07-27 2023-08-22 轨迹Ip有限责任公司 用于提高药物、补充剂和摄入物质的生物利用度的组合物
WO2020019033A1 (en) * 2018-07-25 2020-01-30 Palmer Raymond Denis Container for amylase inhibitor delivery
CA3138922A1 (en) 2019-05-10 2020-11-19 Locus Ip Company, Llc Compositions and methods for treating biofilm-related lung conditions
US11918570B2 (en) 2020-04-13 2024-03-05 The Research Foundation For The State University Of New York Method of treatment for prevention of glucocorticoid toxicity and/or enhancement of muscle regeneration via neutrophil elastase inhibition
WO2023150267A1 (en) * 2022-02-03 2023-08-10 Maison Amori Oqvpo Llc Methods, compositions and uses for treating cancer by providing medications that induce targeted tumor cell mitosis before providing chemotherapy or radiation and kits therefor

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8712176D0 (en) * 1987-05-22 1987-06-24 Cosmas Damian Ltd Drug delivery system
US5122804A (en) * 1987-11-30 1992-06-16 Radar Data Systems, Inc. Method and apparatus for ground radar information display system
DK49791D0 (da) * 1991-03-20 1991-03-20 Novo Nordisk As Nasalt pulverpraeparat
US5650386A (en) * 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
US20020132803A1 (en) * 2001-01-05 2002-09-19 Mahendra Dedhiya Fluticasone suspension formulation, spray pattern method, and nasal spray apparatus

Also Published As

Publication number Publication date
WO2005004895A3 (en) 2005-09-15
US20050031549A1 (en) 2005-02-10
CA2528465A1 (en) 2005-01-20
EP1643970A2 (en) 2006-04-12
JP2007500243A (ja) 2007-01-11
WO2005004895A2 (en) 2005-01-20

Similar Documents

Publication Publication Date Title
MXPA05013340A (es) Composiciones y metodos para liberacion mucosal incrementada de la hormona del crecimiento.
MXPA05006572A (es) Composiciones y metodos para la administracion mejorada por via mucosa de peptidos fijadores al receptor de y2 y metodos para tratar y prevenir la obesidad.
AU2003301190A1 (en) Administration of capsaicinoids
HK1099707A1 (en) Insulin compositions with improved absorption
MXPA03007837A (es) Composiciones para suministrar bisfosfonatos.
GEP20053473B (en) High Potency Dihydroergotamine Compositions
MXPA04004842A (es) Inhibidores de 11-(-hidroxiesteroide deshidrogenasa de tipo 1.
MXPA04004837A (es) Inhibidores de 11-??-hidroxiesteroide deshidrogenasa de tipo 1.
IL161154A0 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
IL190838A0 (en) Intranasal administration of rapid acting insulin
AU7315301A (en) Compounds and compositions for delivering active agents
MY139203A (en) Pharmaceutical composition
MXPA04004567A (es) Compuestos y composiciones de fenoxi amina para adminstrar agentes activos.
MXPA03007857A (es) Compuestos y composiciones para entregar agentes activos.
EA200501105A1 (ru) Фармацевтическая композиция
PL366379A1 (en) Combination therapies with vascular damaging activity
RS44204A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
GB2446341A (en) Method and system for transdermal drug delivery
WO2003106640A3 (en) CELL TARGETING METHODS AND COMPOSITIONS
RS44304A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
TNSN05162A1 (en) Compositions and methods for enhanced mucosal delivery of y2 receptor-binding peptides and methods for treating and preventing obesity
EA201000501A1 (ru) Фармацевтическая композиция, содержащая не обладающий нейротоксичностью активатор плазминоген для лечения удара
BG106430A (en) Liquid mucoadhesive pharmaceutical composition
DE60309926D1 (de) Steroid-verbindungen mit anti-tumoraler wirkung
AU8716001A (en) Treatment of hepatitis c with thymosin and pegylated interferon

Legal Events

Date Code Title Description
FA Abandonment or withdrawal